SG11202100170RA - Antibody molecules that bind pd-l1 and cd137 - Google Patents

Antibody molecules that bind pd-l1 and cd137

Info

Publication number
SG11202100170RA
SG11202100170RA SG11202100170RA SG11202100170RA SG11202100170RA SG 11202100170R A SG11202100170R A SG 11202100170RA SG 11202100170R A SG11202100170R A SG 11202100170RA SG 11202100170R A SG11202100170R A SG 11202100170RA SG 11202100170R A SG11202100170R A SG 11202100170RA
Authority
SG
Singapore
Prior art keywords
bind
antibody molecules
antibody
molecules
Prior art date
Application number
SG11202100170RA
Other languages
English (en)
Inventor
Matthew Lakins
Jose Munoz-Olaya
Francisca Wollerton
Sarah Batey
Mihriban Tuna
Alexander Koers
Original Assignee
F Star Beta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1811405.8A external-priority patent/GB201811405D0/en
Priority claimed from GBGB1818283.2A external-priority patent/GB201818283D0/en
Priority claimed from GBGB1902594.9A external-priority patent/GB201902594D0/en
Application filed by F Star Beta Ltd filed Critical F Star Beta Ltd
Publication of SG11202100170RA publication Critical patent/SG11202100170RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202100170RA 2018-07-12 2019-07-12 Antibody molecules that bind pd-l1 and cd137 SG11202100170RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1811405.8A GB201811405D0 (en) 2018-07-12 2018-07-12 Antibody molecules that bind PD-L1 and CD137
GBGB1818283.2A GB201818283D0 (en) 2018-11-09 2018-11-09 Antibody molecules that bind PD-L1 and CD137
GBGB1902594.9A GB201902594D0 (en) 2019-02-26 2019-02-26 Antibody molecules that bind pd-l1 and cd137
PCT/EP2019/068793 WO2020011964A1 (fr) 2018-07-12 2019-07-12 Molécules d'anticorps qui se lient à pd-l1 et cd137

Publications (1)

Publication Number Publication Date
SG11202100170RA true SG11202100170RA (en) 2021-02-25

Family

ID=67303457

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100170RA SG11202100170RA (en) 2018-07-12 2019-07-12 Antibody molecules that bind pd-l1 and cd137

Country Status (13)

Country Link
US (1) US20220049007A1 (fr)
EP (1) EP3820569A1 (fr)
JP (2) JP7360440B2 (fr)
KR (1) KR20210030956A (fr)
CN (1) CN112423845A (fr)
AU (1) AU2019301204A1 (fr)
BR (1) BR112021000394A2 (fr)
CA (1) CA3106046A1 (fr)
IL (1) IL280004A (fr)
MX (1) MX2021000398A (fr)
SG (1) SG11202100170RA (fr)
TW (1) TW202005984A (fr)
WO (1) WO2020011964A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CN111741976A (zh) 2017-12-19 2020-10-02 F星贝塔有限公司 包括pd-l1抗原结合位点的fc结合片段
KR20210005169A (ko) 2018-04-25 2021-01-13 프로메테우스 바이오사이언시즈, 인크. 최적화된 항tl1a 항체
MX2022004942A (es) 2019-10-24 2022-07-27 Prometheus Biosciences Inc Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos.
IL294967A (en) * 2020-02-04 2022-09-01 Genmab As Antibodies for use in therapy
JP7434593B2 (ja) 2020-05-14 2024-02-20 エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド 抗ｐｄ－ｌ１抗体及び抗ｐｄ－ｌ１／ｉｌ１０融合タンパク質
AU2022339953A1 (en) * 2021-09-03 2024-02-29 Novarock Biotherapeutics, Ltd. BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGFβ AND USES THEREOF
CN114702569B (zh) * 2022-05-25 2023-01-10 深圳吉诺因生物科技有限公司 Pd-l1相关疫苗及其应用
WO2024040194A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0683675A4 (fr) 1993-01-28 1997-05-21 Sandoz Pharmaceuticals Corp Anticorps monoclonaux humains contre le cytomegalovirus.
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
PT2028193E (pt) 2005-01-05 2012-06-15 Star Biotech Forschung Entw Gmbh Domínios de imunoglobulina sintéticos com propriedades de ligação modificadas em regiões da molécula diferentes das regiões de determinação de complementaridade
EP2113255A1 (fr) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Immunoglobuline cytotoxique
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
BR122021025338B1 (pt) 2009-11-24 2023-03-14 Medimmune Limited Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos
RU2551963C2 (ru) 2010-09-09 2015-06-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1вв
CN107636014B (zh) 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
HUE056201T2 (hu) * 2015-07-30 2022-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
SG11201805532XA (en) * 2016-01-11 2018-07-30 Inhibrx Inc Multivalent and multispecific 41bb-binding fusion proteins
EA201990578A1 (ru) 2016-09-23 2019-10-31 Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой
AU2018309339A1 (en) 2017-08-04 2020-02-20 BioNTech SE Binding agents binding to PD-L1 and CD137 and use thereof

Also Published As

Publication number Publication date
BR112021000394A2 (pt) 2021-04-06
KR20210030956A (ko) 2021-03-18
WO2020011964A1 (fr) 2020-01-16
CA3106046A1 (fr) 2020-01-16
US20220049007A1 (en) 2022-02-17
MX2021000398A (es) 2021-05-27
JP2021524268A (ja) 2021-09-13
IL280004A (en) 2021-03-01
JP7360440B2 (ja) 2023-10-12
AU2019301204A1 (en) 2021-02-25
TW202005984A (zh) 2020-02-01
EP3820569A1 (fr) 2021-05-19
CN112423845A (zh) 2021-02-26
JP2023181176A (ja) 2023-12-21

Similar Documents

Publication Publication Date Title
IL280004A (en) Antibody molecules that bind PD-L1 and CD137
HK1247213A1 (zh) Pd-l1抗體、其抗原結合片段及其醫藥用途
IL275510A (en) Specific antigen-binding molecules-ROR1
IL260846B (en) Antigen binding proteins that bind pd-l1
IL287565A (en) Antibodies that bind cd39 and uses thereof
DK3370768T3 (da) Antistoffer som specifikt binder pd-1 og anvendelser deraf
HUE050556T2 (hu) Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai
IL280002A (en) Antibody molecules that bind CD137 and OX40
IL271696A (en) Agonist antibodies that bind human CD137 and their use
SG11202005692WA (en) Antibodies binding ctla-4 and uses thereof
GB2597851B (en) Antibody molecules that bind to NKP30 and uses thereof
SG10201912366YA (en) Anti-cd3 antibody and molecules comprising the antibody
IL275577A (en) Antibodies and their variants against PD-L1
GB2595980B (en) Anti-TCR antibody molecules and uses thereof
GB2607452B (en) Anti-TCR antibody molecules and uses thereof
GB2598218B (en) Anti-TCR antibody molecules and uses thereof
SG11202103221QA (en) Anti pd-l1 antibody and use thereof
IL292799A (en) Antibodies against siglec-9
EP3322445A4 (fr) Agents de liaison à un anticorps qui se lient à l'acinetobacter et leurs utilisations
GB201818283D0 (en) Antibody molecules that bind PD-L1 and CD137
GB201811405D0 (en) Antibody molecules that bind PD-L1 and CD137
GB201902594D0 (en) Antibody molecules that bind pd-l1 and cd137
GB201818281D0 (en) Antibody molecules that bind CD137 and OX40
GB201811407D0 (en) Antibody molecules that bind CD137 and OX40
GB201902598D0 (en) Antibody molecules that bind cd137 and ox40